Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.57 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NQO2 | P16083 | 2/20 | 0.48 |
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29473770 | 1.00 | GPR84 (0.57) | GPR84IMPDH2ALDH1A1HTR2ANPSR1 | |
| SCHEMBL436143 | 0.83 | ALDH1A1 (0.52) | GPR84IMPDH2ALDH1A1KDM4ENQO2 | |
| SCHEMBL9792810 | 0.83 | ALDH1A1 (0.50) | GPR84IMPDH2ALDH1A1HTR2ANPSR1 | |
| Indole SCHEMBL28982138 | 0.80 | AHR (0.52) | GPR84IMPDH2ALDH1A1KDM4ECCNE2 | |
| SCHEMBL3841620 | 0.76 | HTR6 (0.46) | GPR84HTR2AKDM4ENQO2GPR3 | |
| SCHEMBL21035552 | 0.76 | GPR84 (0.57) | GPR84IMPDH2ALDH1A1HTR2ANPSR1 | |
| SCHEMBL10395712 | 0.76 | GPR84 (0.57) | GPR84IMPDH2ALDH1A1HTR2ANPSR1 | |
| SCHEMBL11954801 | 0.76 | SLC6A2 (0.41) | GPR84KDM4ENQO2GPR3MAPT | |
| SCHEMBL13335100 | 0.76 | GPR84 (0.52) | GPR84IMPDH2ALDH1A1HTR2ANPSR1 | |
| SCHEMBL8738068 | 0.76 | GPR84 (0.52) | GPR84IMPDH2ALDH1A1HTR2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307461-A | Preparation method of light-induced palladium-catalyzed difluoro methylene indole compound | 大连理工大学 | 2024-07-09 | — | — | CN | claimed |
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-04 | — | — | US | claimed |
| CN-116924964-A | Preparation method of tetrahydrocarbazole ring compound | 四川轻化工大学 | 2023-10-24 | — | — | CN | claimed |
| CN-113121318-B | Biheteroaromatic hydrocarbon compound and preparation method thereof | 浙江工业大学 | 2022-04-26 | — | — | CN | claimed |
| CN-113121318-A | Biheteroaromatic hydrocarbon compound and preparation method thereof | 浙江工业大学 | 2021-07-16 | — | — | CN | claimed |
| CN-107074822-A | It is used as the triazole compounds of T-shaped calcium channel blocker | 埃科特莱茵药品有限公司 | 2017-08-18 | — | — | CN | claimed |
| US-9486892-B2 | Polishing composition | FUJIMI INCORPORATED (JP) | 2016-11-08 | — | — | US | claimed |
| EP-1255797-B2 | METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES | OMG ELECTRONIC CHEMICALS INC (US) | 2016-10-12 | — | — | EP | claimed |
| CN-105037422-A | Preparation method of indole phosphonate derivative | UNIV SOOCHOW | 2015-11-11 | — | — | CN | claimed |
| CN-104926868-A | Method for preparing indole phosphonate derivative | ZHANGJIAGANG INST IND TECHNOLOGIES SOOCHOW UNIV | 2015-09-23 | — | — | CN | claimed |
| US-5656604-A | HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | claimed |
| US-5571793-A | COMBATTING ENDOPARASITES IN HUMANS OR ANIMALS BY ADMINISTERING PEPTIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-05 | — | — | US | claimed |
| WO-1996026183-A1 | 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS | NOVARTIS AG (CH) | 1996-08-29 | — | — | WO | claimed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | claimed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | claimed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | claimed |
| EP-0181152-B1 | PIPERAZINE COMPOUND AS PAF-ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-13 | — | — | EP | claimed |
| EP-0243122-A2 | Piperazine compound as PAF-antagonist | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-28 | — | — | EP | claimed |
| EP-0181152-A1 | Piperazine compound as PAF-antagonist | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | claimed |
| US-4199512-A | Compounds for alleviating hypertension | E. R. SQUIBB & SONS, INC. (US) | 1980-04-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | VIP, SGTA, NGLY1 | GPR84 1953/4885IMPDH2 3787/4885ALDH1A1 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.